Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00199888 · ClinicalTrials.gov registry record · Phase 1
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00199888 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 26 participants.
The verdict
NCT00199888, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
Interventions
- DRUG 124-Iodine-cG250 (124I-cG250)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00199888
The ClinicalTrials.gov registry entry for NCT00199888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 124-Iodine-cG250 (124I-cG250) is the first listed.
NCT00199888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00199888 about?
NCT00199888 is a clinical study titled "Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.". The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
What is the current status of trial NCT00199888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2005-06. Estimated completion is 2009-05-29.
What interventions are being tested in trial NCT00199888?
The interventions under investigation include: 124-Iodine-cG250 (124I-cG250) (DRUG).
Who is sponsoring clinical trial NCT00199888?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.